UpdatesPress Release
Cohance Lifesciences advances its ADC strategy with a USD 13 million additional investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio.
Cohance Lifesciences LimitedCOHANCE · Filed with the exchange
This reorganisation, funded by internal accruals, strengthens integration and pipeline development.
No comments yet. Be the first.